Along with researchers in the Faculty of Health Sciences and the Faculty of Science, Western projects received a total of $17 ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

Low-fat diets are problematic, says world-renowned internist and regenerative physician Michael Aziz, MD, author of the ...

Glutathione has been nicknamed the "master antioxidant," but some people are buying it online and self-injecting it, which ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Dr. Scott Loessin, a distinguished board-certified plastic surgeon, is redefining body contouring for individuals who have achieved significant weight loss through medications like Ozempic or other ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic and reconstructive surgeons, has released its highly anticipated 2024 ...